通过瘤内注射基因工程改造的塞姆利基森林病毒以产生白细胞介素-12来诱导治疗性抗肿瘤免疫反应。

Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12.

作者信息

Yamanaka R, Zullo S A, Tanaka R, Ramsey J, Blaese M, Xanthopoulos K G

机构信息

Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

Neurosurg Focus. 2000 Dec 15;9(6):e7. doi: 10.3171/foc.2000.9.6.8.

DOI:10.3171/foc.2000.9.6.8

PMID:16817690

Abstract

OBJECT

The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved.

METHODS

Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-12, and SFV-IL12, respectively. The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity.

CONCLUSIONS

Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines.

摘要

目的

作者研究恶性胶质瘤的免疫基因治疗，以确定其治疗效果是否可以提高。

方法

四组各20只荷胶质瘤小鼠分别接受磷酸盐缓冲盐水、辛德毕斯病毒（SFV）-LacZ、逆转录病毒载体DFG-白细胞介素（IL）-12和SFV-IL12注射治疗。结果表明，用SFV-IL12进行治疗性免疫可延长已形成肿瘤小鼠的生存期。辛德毕斯病毒可诱导胶质瘤细胞凋亡死亡，这有利于树突状细胞摄取凋亡细胞，为增强免疫原性提供了一种潜在机制。